NCT01216436View on ClinicalTrials.gov

Local Modulation of Immune Receptors to Enhance the Response to Dendritic Cell Vaccination in Metastatic Melanoma

PHASE1TerminatedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

January 31, 2010

Primary Completion Date

October 31, 2013

Study Completion Date

October 31, 2013

Conditions
Metastatic Melanoma
Interventions
BIOLOGICAL

Vaccination with RNA-transfected mature autologous DC

Dendritic cells (DC) will be administered at a dose of 20 million cells by intranodal injection under ultrasound guidance. Each subject will receive a total of six vaccinations at one week intervals

Trial Locations (1)

27710

Duke University Medical Center, Durham

Sponsors

Lead Sponsor

Duke University
All Listed Sponsors
lead

Duke University

OTHER

NCT01216436 - Local Modulation of Immune Receptors to Enhance the Response to Dendritic Cell Vaccination in Metastatic Melanoma | Biotech Hunter | Biotech Hunter